Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) Equity Ratio (2016 - 2025)

Immucell's Equity Ratio history spans 16 years, with the latest figure at 0.64 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 4.25% year-over-year to 0.64; the TTM value through Dec 2025 reached 0.64, up 4.25%, while the annual FY2025 figure was 0.64, 4.25% up from the prior year.
  • Equity Ratio reached 0.64 in Q4 2025 per ICCC's latest filing, down from 0.65 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.74 in Q2 2021 to a low of 0.56 in Q2 2024.
  • Average Equity Ratio over 5 years is 0.65, with a median of 0.65 recorded in 2025.
  • Peak YoY movement for Equity Ratio: dropped 15.76% in 2023, then grew 14.08% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.73 in 2021, then decreased by 7.56% to 0.68 in 2022, then decreased by 15.76% to 0.57 in 2023, then rose by 6.95% to 0.61 in 2024, then increased by 4.25% to 0.64 in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Equity Ratio are 0.64 (Q4 2025), 0.65 (Q3 2025), and 0.64 (Q2 2025).